ATP6V1B2 Antibody (monoclonal) (M02)
Mouse monoclonal antibody raised against a full length recombinant ATP6V1B2.
|Calculated MW||56501 Da|
|Other Names||V-type proton ATPase subunit B, brain isoform, V-ATPase subunit B 2, Endomembrane proton pump 58 kDa subunit, HO57, Vacuolar proton pump subunit B 2, ATP6V1B2, ATP6B2, VPP3|
|Target/Specificity||ATP6V1B2 (AAH03100, 1 a.a. ~ 511 a.a) full-length recombinant protein with GST tag. MW of the GST tag alone is 26 KDa.|
|Format||Clear, colorless solution in phosphate buffered saline, pH 7.2 .|
|Storage||Store at -20°C or lower. Aliquot to avoid repeated freezing and thawing.|
|Precautions||ATP6V1B2 Antibody (monoclonal) (M02) is for research use only and not for use in diagnostic or therapeutic procedures.|
firstname.lastname@example.org, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
This gene encodes a component of vacuolar ATPase (V-ATPase), a multisubunit enzyme that mediates acidification of eukaryotic intracellular organelles. V-ATPase dependent organelle acidification is necessary for such intracellular processes as protein sorting, zymogen activation, receptor-mediated endocytosis, and synaptic vesicle proton gradient generation. V-ATPase is composed of a cytosolic V1 domain and a transmembrane V0 domain. The V1 domain consists of three A, three B, and two G subunits, as well as a C, D, E, F, and H subunit. The V1 domain contains the ATP catalytic site. The protein encoded by this gene is one of two V1 domain B subunit isoforms and is the only B isoform highly expressed in osteoclasts.
1.The histone deacetylase inhibitor trichostatin A reduces lysosomal pH and enhances cisplatin-induced apoptosis.Eriksson I, Joosten M, Roberg K, Ollinger K.Exp Cell Res. 2013 Jan 1;319(1):12-20. doi: 10.1016/ j.yexcr.2012.10.004. Epub 2012 Oct 12.2.Intrinsic differences in cisplatin sensitivity of head and neck cancer cell lines: Correlation to lysosomal pH.Nilsson C, Roberg K, Grafstrom RC, Ollinger K.Head Neck. 2010 Sep;32(9):1185-94.
If you have any additional inquiries please email technical services at email@example.com.